News digest – vitamin supplements, cancer ‘avatars’, immunotherapy targets, and… Wi-Fi worries? – Cancer Research UK (blog)
Cancer Research UK (blog) |
News digest – vitamin supplements, cancer ‘avatars’, immunotherapy targets, and… Wi-Fi worries?
Cancer Research UK (blog) Men who take high doses of some vitamin B supplements might be at higher risk of lung cancer, particularly if they smoke, according to a US study. Taking daily supplements that far exceed the recommended intake for 10 years increased the risk of lung … |
|
New ‘Dimension’ expands the gene therapy pipeline for Regenxbio
BioWorld Online The deal, which values Dimension at less than $100 million, adds gene therapy candidates DTX-301 for ornithine transcarbamylase (OTC) deficiency and DTX-401 for glycogen storage disease type Ia (GSDIa) to Regenxbio’s metabolic disease franchise, … |
Southernminn.com |
Mayo Clinic, University of Minnesota develop ‘robocop’ stem cells to fight cancer
Southernminn.com The so-called CAR T cellular therapies are expected to receive federal approval this fall for certain rare blood cancers — B-cell forms of lymphoma and leukemia. But scientists at the Minnesota institutions hope that’s just the first step that will … Blood Cancer 101 comes to Oak BayVictoria News |
Community Idea Stations |
Life By Design: A Century of Synthetic Biology
Community Idea Stations Newspapers today are full of accounts of the future marvels of “synthetic biology,” a new approach to engineering life. But, how new is it? Dr. Luis Campos takes us through the surprising history in an informal 20-minute talk followed by a Q & A given … |
|
Case Study Identifies New Trigger for CAR–T Cell Expansion in DLBCL in JCAR017 Trial
AJMC.com Managed Markets Network Chimeric antigen receptor (CAR)-T cells can re-expand in a patient months after the initial infusion and can also be active against the patient’s cancer. These are the findings of a single case study that was recently published in the New England … |
Xconomy |
RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy Companies
Xconomy Dimension Therapeutics has agreed to be acquired by RegenxBio, the gene therapy developer that originally helped form the company four years ago. RegenxBio, based in Rockville, MD, will pay $3.41 per share in the all-stock deal. By comparison … Regenxbio bags one of its gene therapy vector partners, buying out a struggling DimensionEndpoints News Regenxbio to buy battered Dimension for gene therapiesFierceBiotech Rockville biotech buys Cambridge gene therapy firm for $86MWashington Business Journal Genetic Engineering & Biotechnology News –BioPharma Dive all 21 news articles » |
Genetic Literacy Project |
Five myths about gene editing
Washington Post In February 2016, one CRISPR critic predicted in Mother Jones, “We are this close to ‘designer babies.’ ” And this month, biologist Richard Dawkins mused that the genetically edited “designer babies ” on the horizon shouldn’t be any more worrisome than … CRISPR co-creator: We should have freedom to choose our ‘genetic destiny’Genetic Literacy Project |